Arrowhead axes heart disease drug, goes all in on another as pipeline progress drives costs up

With two cardiovascular disease candidates in or near phase 3, RNAi specialist Arrowhead Pharmaceuticals has dropped one prospect and thrown its weight behind the other to manage its spending.